Developing long-acting HIV treatments for children
Official title: Dose flexible ultra-long-acting prodrug formulations for pediatric populations
Funded at University of Nebraska Medical Center · NIH-11055903 · Data updated 2026-11-12
This study is testing a new injectable medicine for kids with HIV-1 that they would only need to get every six months, making it easier and more effective than taking daily pills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | January 17, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,228,661 |
| NIH project number | 1R61AI188553-01 |
| Project ID | NIH-11055903 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0 to 11 years who are living with HIV-1 infection.
✕Less likely to help
Patients who are not living with HIV-1 or are older than 11 years may not benefit from this research.
What this research studies
This research focuses on creating a new injectable medication for children living with HIV-1 that can be administered every six months. By using a novel formulation of a drug called bictegravir, the goal is to provide a more effective and convenient treatment option compared to daily oral medications. The study aims to address the challenges of current treatments, which can be unpredictable in children due to their changing pharmacokinetics. The innovative approach seeks to enhance viral suppression rates and improve adherence to treatment among pediatric patients.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for children with HIV-1, potentially improving their health outcomes.
How similar studies have gone: Other research has shown promise in developing long-acting formulations for HIV treatment, indicating that this approach has potential for success.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Edagwa, Benson — University of Nebraska Medical Center
- Study coordinator: Edagwa, Benson
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Molecular and brain circuits linked to anxiety disorders
A researcher is studying a specific brain circuit to understand what drives anxiety and how it could be treated for people with anxiety disorders.
-
Modulating a brain lipid to reduce injury after newborn brain injury
Aims to test a treatment that changes a brain lipid to lessen damage after a baby’s brain has been deprived of oxygen.
-
Autonomic dysfunction in diabetes and erectile function: brain signals and kidney nerves
A study in diabetic rats explores how brain and kidney nerve signals may contribute to erectile dysfunction in diabetes, with findings that could inform future treatments for men with diabetes who have ED.
-
Multimodal bioelectroceutical approach to bone regeneration in diabetes and aging
A new approach uses electrical signals and tiny drugs inside special scaffolds to help jawbone heal in people with diabetes or aging-related bone problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.